Yates, Rice, Biden, Comey and Obama Met in White House to

New Post Public Reply Private Reply Replies (0) Message Board
Lmcat
466
Yates, Rice, Biden, Comey and Obama Met in White House to Discuss Targeting Mike Flynn

During the infamous January 5, 2017 White House meeting Sally Yates, Susan Rice, Joe Biden, James Comey and Barack Obama discussed how they would target General Michael Flynn.

This is a huge development!

1. Mueller has told close confidants he was handed “a piece of crap on collusion.” But investigated it further with no fruits.

2. DiGenova mentions, “James Baker, former FBI General Counsel, is a cooperating witness in a case against James Comey.”

3. DiGenova says there will be one more indictment related to Lying to the FBI. However “the Mueller Probe is coming to an end with NO indictments about collusion whatsoever.”

4. DiGenova: “This is going to be a bad next 30 days for a bunch of people in the FBI and DOJ under Obama.” This is in relation to the declassification of the FISA documents for Carter Page which is in process.

5. DiGenova also brings up the January 5th, 2017 meeting with Rice, Yates, Biden, Comey, and Obama. He says “It was a meeting to discuss how Sally Yates was going to get Michael Flynn. And the President of the United States, Barack Obama, was directly involved in these discussions.”

This is another bombshell itself, and deserves a whole article.

https://www.thegatewaypundit.com/2018/09/huge...a-18689133

BOMBSHELL: Comey Held Secret Obama White House Meeting Before The Inauguration [/b

FBI Director James Comey held a secret Oval Office meeting with President Barack Obama two weeks before Trump’s inauguration and may have deliberately misled Congress about it, according to an email sent by National Security Advisor Susan Rice that GOP Sens. Chuck Grassley and Lindsey Graham partially unclassified.

The meeting — which Comey never previously disclosed to Congress — occurred in the White House on Jan. 5, 2017.
It included Obama, Joe Biden, Rice deputy Attorney General Sally Yates, and Comey. The topic of the meeting was potential Russian interference in the 2016 presidential election.

By failing to inform the Senate Select Committee on Intelligence about the meeting in his June 8, 2017, testimony, Comey may have deliberately and intentionally misled Congress about his interactions with the former president, especially a meeting so close to Trump entering the White House.

“President Obama had a brief follow-on conversation with FBI Director Comey and Sally Yates in the Oval Office,” Rice wrote in an email written the day before the inauguration.

The National Archives gave Grassley and Graham “classified and unclassified emails” about the meeting.

Previously, Comey contended he only met with the Obama twice, once in 2015 and another “to say goodbye in late 2016,” according the former FBI director’s June 8, 2017, testimony before the Senate Select Committee on Intelligence.

“I spoke alone with President Obama twice in person (and never on the phone) – once in 2015 to discuss law enforcement policy issues and a second time, briefly, for him to say goodbye in late 2016,” Comey’s opening statement read.

Grassley and Graham stated on their websites they “were struck by the context and timing of this email, and sent a follow up letter to Ambassador Rice.”

“It strikes us as odd that, among your activities in the final moments on the final day of the Obama administration, you would feel the need to send yourself such an unusual email purporting to document a conversation involving President Obama and his interactions with the FBI regarding the Trump/Russia investigation,” the two senators told Rice.

“In addition, despite your claim that President Obama repeatedly told Mr. Comey to proceed ‘by the book,’ substantial questions have arisen about whether officials at the FBI, as well as at the Justice Department and the State Department, actually did proceed ‘by the book,'”

they continued.

Rice was scheduled to testify before the Senate Committee on the Judiciary on Feb. 22 but she declined. WHAT IS SHE HIDING?

Grassley co-authored the letter to Rice as chairman of the Senate Committee on the Judiciary and Graham as chairman of the Subcommittee on Crime and Terrorism.

https://dailycaller.com/2018/02/13/comey-obam...t-meeting/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into AppLovin Corporation's Alleged Fraud

Updated Category News Views 386

Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...

Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators

Updated Category News Views 33

Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...

Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights

Updated Category News Views 224

Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...

Continue Reading
Understanding HCI Group's Short Interest Trends and Insights

Updated Category News Views 126

An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...

Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients

Updated Category News Views 151

Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...

Continue Reading